Extracorporeal Photopheresis as a Treatment Option for Immune-Related Adverse Events: Two Case Reports and a Prospective Study
Ruf T, Rahimi F, Anz D, Tufman A, Salzer S, Zierold S, Tomsitz D, French LE, Heinzerling L (2024)
Publication Type: Journal article
Publication year: 2024
Journal
Book Volume: 47
Pages Range: 227-231
Journal Issue: 6
DOI: 10.1097/CJI.0000000000000510
Abstract
The wide use of immune checkpoint inhibitors has increased the frequency of immune-related adverse events (irAEs). While many are managed with corticosteroids or hormone substitution, up to 14.9% of irAEs are steroid-refractory or steroid-dependent and thus require second-line treatment. These should reduce irAE-related morbidity and mortality and induce a few side effects of their own while maintaining the antitumor response. There is little comparative data on second-line therapies for irAEs. Two cases of irAEs could not be sufficiently managed with corticosteroids and subsequently received treatment with extracorporeal photopheresis (ECP), including one patient with immune-related erosive oral lichen planus and one patient with immune-related colitis. In both cases, the irAE resolved with ECP in combination with immunosuppressive drugs, that is 4 weeks and 10 weeks after the start of ECP, respectively. To investigate this approach, a prospective clinical study that compares ECP and other second-line therapies for the treatment of steroid-refractory and steroid-dependent irAEs with regard to immunophenotype and therapy response has been designed. ECP could be a treatment option for steroid-refractory and steroid-dependent irAEs, given its good safety profile and lack of adverse effects on antitumor response. Comparative prospective studies are needed to generate an evidence base.
Involved external institutions
Germany (DE)How to cite
APA:
Ruf, T., Rahimi, F., Anz, D., Tufman, A., Salzer, S., Zierold, S.,... Heinzerling, L. (2024). Extracorporeal Photopheresis as a Treatment Option for Immune-Related Adverse Events: Two Case Reports and a Prospective Study. Journal of Immunotherapy, 47(6), 227-231. https://doi.org/10.1097/CJI.0000000000000510
MLA:
Ruf, Theresa, et al. "Extracorporeal Photopheresis as a Treatment Option for Immune-Related Adverse Events: Two Case Reports and a Prospective Study." Journal of Immunotherapy 47.6 (2024): 227-231.
BibTeX: Download